SPA
FHTX icon

Sherbrooke Park Advisers’s Foghorn Therapeutics FHTX Stock Holding History

Sherbrooke Park Advisers’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,075
Closed -$47.7K – 597
2025
Q1 		$47.7K Sell
13,075
-2,542
-16% -$11.6K 0.02% 551
2024
Q4 		$73.7K Buy
15,617
+2,841
+22% +$20.7K 0.02% 694
2024
Q3 		$119K Buy
+12,776
New +$92.5K 0.03% 821

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sherbrooke Park Advisers's FHTX Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Foghorn Therapeutics (FHTX) in Q2 2025, closing a stake of 13,075 shares — an estimated $47.7K sold.

Sherbrooke Park Advisers first reported a position in FHTX in Q3 2024 and held it in 3 quarters. The position peaked at $119K in Q3 2024. 81 funds tracked by Wall St. Rank hold FHTX as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Foghorn Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,075 Foghorn Therapeutics shares in Q2 2025, an estimated $47.7K.
  • Sherbrooke Park Advisers first reported a position in Foghorn Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Foghorn Therapeutics position peaked at $119K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.